- Author:
Min PAN
1
;
Shuang CHANG
1
;
Xiao-Xia FENG
1
;
Guang-He FEI
1
;
Jia-Bin LI
1
;
Hua WANG
1
;
Du-Juan XU
1
;
Chang-Hui WANG
1
;
Yan SUN
1
;
Xiao-Yun FAN
1
;
Tian-Jing ZHANG
2
;
Wei WEI
2
;
Ling-Ling ZHANG
2
;
Jim LI
3
;
Fei-Hu CHEN
3
;
Xiao-Ming MENG
3
;
Hong-Mei ZHAO
4
;
Min DAI
5
;
Yi XIANG
6
;
Meng-Shu CAO
7
;
Xiao-Yang CHEN
8
;
Xian-Wei YE
9
;
Xiao-Wen HU
10
;
Ling JIANG
10
;
Yong-Zhong WANG
11
;
Hao LIU
12
;
Hai-Tang XIE
13
;
Ping FANG
14
;
Zhen-Dong QIAN
15
;
Chao TANG
16
;
Gang YANG
17
;
Xiao-Bao TENG
18
;
Chao-Xia QIAN
19
;
Guo-Zheng DING
20
Author Information
- Publication Type:Journal Article
- Keywords: antiviral drugs; clinical rational use; COVID-19; drug interactions; the elderly; treatment advice
- From: Chinese Pharmacological Bulletin 2023;39(3):425-430
- CountryChina
- Language:Chinese
- Abstract: COVID-19 has been prevalent for three years. The virulence of SARS-CoV-2 is weaken as it mutates continuously. However, elderly patients, especially those with underlying diseases, are still at high risk of developing severe infections. With the continuous study of the molecular structure and pathogenic mechanism of SARS-CoV-2, antiviral drugs for COVID-19 have been successively marketed, and these anti-SARS-CoV-2 drugs can effectively reduce the severe rate and mortality of elderly patients. This article reviews the mechanism, clinical medication regimens, drug interactions and adverse reactions of five small molecule antiviral drugs currently approved for marketing in China, so as to provide advice for the clinical rational use of anti-SARS-CoV-2 in the elderly.